Non Small Cell Lung Cancer Positive For Epidermal Growth Factor Receptor Expression — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for non small cell lung cancer positive for epidermal growth factor receptor expression. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

Originators in Non Small Cell Lung Cancer Positive For Epidermal Growth Factor Receptor Expression

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating non small cell lung cancer positive for epidermal growth factor receptor expression. Each bar = one year. Y-axis scaled to peak year (3 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Non Small Cell Lung Cancer Positive For Epidermal Growth Factor Receptor Expression — full disease profile
• AI Patent Landscape Report — type "non small cell lung cancer positive for epidermal growth factor receptor expression" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner